Unexpected effect of verapamil on oral bioavailability of the β‐blocker talinolol in humans
暂无分享,去创建一个
W. Kirch | U. Schwarz | R. Oertel | T. Gramatté | O. Richter | J. Krappweis | A. Berndt
[1] P. Watkins,et al. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. , 1997, Advanced drug delivery reviews.
[2] K. Paull,et al. P-glycoprotein substrates and antagonists cluster into two distinct groups. , 1997, Molecular pharmacology.
[3] G. Ecker,et al. Recent developments in overcoming tumour cell multi-drug resistance , 1997 .
[4] B. Hirst,et al. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption , 1997 .
[5] Leslie Z. Benet,et al. Intestinal drug metabolism and antitransport processes : A potential paradigm shift in oral drug delivery , 1996 .
[6] W. Kirch,et al. Direct demonstration of small intestinal secretion and site‐dependent absorption of the β‐blocker talinolol in humans , 1996, Clinical pharmacology and therapeutics.
[7] E. Schuetz,et al. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. , 1996, Molecular pharmacology.
[8] S. Dei,et al. Reversal of multidrug resistance by verapamil analogues. , 1995, Biochemical pharmacology.
[9] C. Cordon-Cardo,et al. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] L. Benet,et al. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.
[11] R. Oertel,et al. Disposition and bioavailability of the β1‐adrenoceptor antagonist talinolol in man , 1995, Biopharmaceutics & drug disposition.
[12] U. S. Rao,et al. Mutation of glycine 185 to valine alters the ATPase function of the human P-glycoprotein expressed in Sf9 cells. , 1995 .
[13] J. Crowley,et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study , 1995, Cancer.
[14] W. Kirch,et al. Elucidation of the structure of talinolol metabolites in man. Determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum. , 1994, Journal of chromatography. B, Biomedical applications.
[15] B. Sikic,et al. Clinical trials of modulation of multidrug resistance pharmacokinetic and pharmacodynamic considerations , 1993, Cancer.
[16] P. Meredith,et al. R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate. , 1993, British journal of clinical pharmacology.
[17] M. Dietel,et al. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. , 1992, Biochemical pharmacology.
[18] H. Sewell,et al. The immunocytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450. , 1988, British journal of clinical pharmacology.
[19] C. Peterson,et al. D‐verapamil and L‐verapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitro , 1988, International journal of cancer.
[20] M C Willingham,et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[21] C H Nightingale,et al. Basic principles of pharmacokinetics. , 1987, Clinics in laboratory medicine.
[22] T. Tsuruo,et al. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. , 1981, Cancer research.
[23] H. Fiehring,et al. On the clinical pharmacology of talinolol, a new beta 1-adrenoceptor blocking agent. , 1979, International journal of clinical pharmacology and biopharmacy.
[24] M. Eichelbaum,et al. The metabolism of DL-[14C]verapamil in man. , 1979, Drug metabolism and disposition: the biological fate of chemicals.
[25] P. Ader,et al. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. , 1998, International journal of clinical pharmacology and therapeutics.
[26] W T Bellamy,et al. P-glycoproteins and multidrug resistance. , 1996, Annual review of pharmacology and toxicology.
[27] I. Pastan,et al. In vivo models of P-glycoprotein-mediated multidrug resistance. , 1994, Cancer treatment and research.
[28] I. Pastan,et al. Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.